Literature DB >> 13679422

Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

Pritam Das1, Victor Howard, Nicole Loosbrock, Dennis Dickson, M Paul Murphy, Todd E Golde.   

Abstract

Direct immunization with amyloid beta protein (Abeta) and passive transfer of anti-Abeta antibodies reduce Abeta accumulation and attenuate cognitive deficits in transgenic models of Alzheimer's disease (AD). The reduction in Abeta deposition has been proposed to involve microglial phagocytosis of Abeta immune complexes via Fc receptors (FcRs). We have examined the efficacy of Abeta immunization in amyloid precursor protein (APP) transgenic mice crossed into FcR-gamma chain knock-out mice (FcRgamma-/-). As might be expected from previous studies on macrophages, phagocytosis of Abeta immune complexes via FcR was completely impaired in microglia cells isolated from FcRgamma-/- mice. Thus, we immunized APP Tg2576 transgenic mice that were crossed in the FcRgamma-/- background with Abeta1-42 and then analyzed the effect on Abeta accumulation. In APP Tg2576 transgenic mice crossed to FcRgamma-/-, Abeta1-42 immunization significantly attenuated Abeta deposition, as assessed by both biochemical and immunohistological methods. The reduction in Abeta accumulation was equivalent to the reduction in deposition seen in Abeta1-42 immunized, age-matched, FcR-sufficient Tg2576 mice. We conclude that after Abeta immunization, the effects of anti-Abeta antibodies on Abeta deposition in APP Tg2576 transgenic mice are not dependent on FcR-mediated phagocytic events.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679422      PMCID: PMC6740360     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  87 in total

1.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

Review 2.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

3.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

Review 4.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 5.  Amyloid-beta immunisation for Alzheimer's disease.

Authors:  Thomas Wisniewski; Uwe Konietzko
Journal:  Lancet Neurol       Date:  2008-07-28       Impact factor: 44.182

6.  Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance.

Authors:  Thierry Bussière; Frédérique Bard; Robin Barbour; Henry Grajeda; Terry Guido; Karen Khan; Dale Schenk; Dora Games; Peter Seubert; Manuel Buttini
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

7.  Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease.

Authors:  Miranda L Bader Lange; Daret St Clair; William R Markesbery; Christa M Studzinski; M Paul Murphy; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2010-01-18       Impact factor: 5.996

8.  An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

Authors:  Einar M Sigurdsson; Elin Knudsen; Ayodeji Asuni; Cheryl Fitzer-Attas; Daniel Sage; David Quartermain; Fernando Goni; Blas Frangione; Thomas Wisniewski
Journal:  J Neurosci       Date:  2004-07-14       Impact factor: 6.167

9.  BACE1 and BACE2 enzymatic activities in Alzheimer's disease.

Authors:  Rachel R Ahmed; Christopher J Holler; Robin L Webb; Feng Li; Tina L Beckett; M Paul Murphy
Journal:  J Neurochem       Date:  2009-12-04       Impact factor: 5.372

10.  A limited role for microglia in antibody mediated plaque clearance in APP mice.

Authors:  Monica Garcia-Alloza; Brian J Ferrara; Sarah A Dodwell; Gregory A Hickey; Bradley T Hyman; Brian J Bacskai
Journal:  Neurobiol Dis       Date:  2007-07-28       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.